Michael Fernando and Josh Hurwitz
Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Be sure to visit the podcast's website and support the creator: www.inquisitiveonc.com
Author
Michael Fernando and Josh Hurwitz
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
172. Back to Basics - Advanced ccRCC 09.08.2025 19:25
Unlike the adjuvant space, treatment of advanced clear cell renal cell cancer has been a success story potentially only surpassed by advanced melanoma. What was once a horrific and quickly fatal disease, with a predilection for the CNS and significant bleeding risk has become significantly less so. In this episode, Josh and Michael explore the studies that have made it happen. Studies discussed in...
171. Back to Basics - Early Clear Cell Renal Cell Cancer (ccRCC) 02.08.2025 14:41
Continuing on their Back to Basics GU extravaganza, Josh and Michael progress to the subject of kidney cancer, and bring you the answer to a question long unanswered: is there any benefit of adjuvant therapy in resected clear cell renal cell cancer. For a long time, this space produced negative study after negative study, until, as is so often the case, immunotherapy swooped in to save the day. St...
170. Back to Basics - Adjuvant Urothelial Cancer 26.07.2025 18:26
Josh and Michael return to their normal scheduled broadcast, continuing their never-ending Back to Basics series. In this episode, they discuss several interesting developments in the adjuvant management of urothelial cancer, focussing on the sometimes contradictory data of adjuvant immunotherapy. This is an emerging area of treatment that you will not want to miss! Studies discussed in this episo...
169. ASCO 2025 - Colorectal Cancer with Prof Jeanne Tie 05.07.2025 33:40
In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the practice changing BREAKWATER study, combining chemotherapy with encorafenib and cetuximab, they also discuss the plenary study ATOMIC III, the CHALLENGE study examining structured exercis...
168. ASCO 2025 - Early Breast Cancer with Dr. Belinda Yeo 03.07.2025 30:31
In this episode, Michael goes it alone, welcoming an old friend of the show, Dr Belinda Yeo, to discuss highlights in early breast cancer from ASCO 2025. The pair discuss an exciting new medication to assist with vasomotor symptoms from endocrine therapy, the ongoing follow up from the pivotal SOFT/TEXT study, an escalation strategy for abemaciclib and a de-escalation strategy for neoadjuvant chem...
167. ASCO 2025 - Upper GI and Hepatobiliary Cancer with Dr. James McCracken 30.06.2025 31:22
Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy...
166. ASCO 2025 - Gynecological Oncology with Dr. Prachi Bhave 28.06.2025 38:44
Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST trial on ovarian cancer surgery timing, the Rosella trial for platinum-resistant ovarian cancer, the FIRST study on immunotherapy in advanced ovarian cancer, and the update on the Keynote A18 trial for c...
165. ASCO 2025 - Palliative Care with Dr. Janet Abrahm 23.06.2025 35:36
In this episode, Dr. Janet Abrahm shares transformative insights from ASCO 2025, focusing on palliative care and supportive care in oncology. Topics discussed include the role of exercise in cancer survival, cannabis use for symptom management, and the challenges of chemotherapy-induced peripheral neuropathy. We also highlight the importance of communication with patients, particularly in the cont...
164. ASCO 2025 - Lung Cancer with Dr. Ned McNamee 22.06.2025 30:30
In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate 816. They explore the implications of these findings for clinical practice, including the challenges of managing immune-related side effects and the potential for neoadjuvant immunotherapy to improve...
163. ASCO 2025 - Genitourinary Cancers (Bladder and Renal) with Dr. Enrique Grande 19.06.2025 35:04
Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us. This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in b...
162. ASCO 2025 - Genitourinary Cancers (Prostate) with Dr. Anthony Joshua 16.06.2025 34:52
Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent’s Hospital, Sydney, and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses multiple trials including AMPLITUDE, advancing prostate cancer therapies; CAN 2409, exploring immunotherapy; ARANOTE, showing darolutamide’s impact on progression-free survival; the prognostic s...
161. ASCO 2025 - Breast Cancer with Dr. Adam Brufsky 15.06.2025 45:59
In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsburgh, with 30 years of experience, whose expertise has helped shape the direction of treatment. Trials discussed include the SERENA-6 trial, which examines camizestrant plus CDK4/6 inhibitors in HR-pos...
160. ASCO 2025 - Plenary Part 2 11.06.2025 25:44
In our second plenary episode, we're spotlighting two pivotal phase 3 trials: SERENA-6, which explores ctDNA-guided treatment with camizestrant to delay progression in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, and NIVOPOSTOP, a landmark study showing improved disease-free survival with adjuvant nivolumab in high-risk, resected head and neck squamous cell carcinoma. Joi...
159. ASCO 2025 - Plenary Part 1 07.06.2025 31:01
This year, Michael and Josh bring you the American Society of Clinical Oncology (ASCO) 2025. To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global host of experts to deliver the very best from the practice-changing, thought-provoking, design-defining trials you know and love from this podcast. This episode focuses on adjuvant atezolizumab in the co...
158. Back to Basics - Metastatic Urothelial (Bladder) Cancer 31.05.2025 20:03
This week, we talk about metastatic bladder cancer. The last two years have seen drastic changes in this space, with the addition of immunotherapy and ADCs in a first-line setting. While exceptionally effective, toxicity and patient selection remain challenging. The other big issue with what's best for the second line? That's the golden question. Studies discussed in the episode: EV-302 THOR For m...
157. Back to Basics - Early Bladder Cancer 24.05.2025 19:05
This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting. It also compared the neoadjuvant to the perioperative space. The second trial u...
156. Back to Basics - Prostate Cancer - Biochemical Recurrence and Oligometastatic Disease Control 17.05.2025 24:26
As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies raise the question of newer technologies and how we apply this information to tri...
155. Back to Basics - Theranostics and Prostate Cancer 10.05.2025 24:13
Marie Curie's life work laid the foundations for theranostics. This week, we talk about Lutetium, a rare earth metal, and its role in Prostate Cancer. Lutetium-177 PSMA therapy is a radiation therapy that targets prostate cancer. It is used in the advanced, metastatic, and castrate-resistant space. Lutetium is bound to a protein called PSMA. PSMA is overexpressed in many prostate cancers and...
154. Back to Basics - Non Metastatic and Metastatic Prostate Cancer - The Journey Continues 03.05.2025 22:09
Prostate Cancer has a multitude of presentations, but when metastatic, it usually spreads directly to the lymph nodes or the bones. This episode focuses on the contentious definition of "M0 Castrate Resistant Prostate Cancer (CRPC)", also known as Nonmetastatic CRPC. Does this definition exist, and what role will PSMA PET have in this cohort of patients? The second trial, TITAN looks at apalutamid...
153. Inflammatory Breast Cancer with Dr Massimo Cristofanilli, M.D. 26.04.2025 31:41
This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liquid biopsy, molecular profiling, and targeted therapies. Dr Cristofanilli serves...
152. Back to Basics - High Volume Metastatic Prostate Cancer 05.04.2025 23:32
Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamide is equivalent to the other androgen receptor signalling inhibitors in the castrate-sensitive space. Two good trials, and as always, some interesting discussion points. Studies discussed in the episod...
151. Back to Basics - Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer 29.03.2025 18:07
The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents. Studies discussed in the episode: ARCHES ENZAMET For more episodes, resources and blog...
150. Back to Basics - Recurrence-Score Assays in Early Breast Cancer 22.03.2025 21:14
Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx! Studies discussed in the episode: TA...
149. Back to Basics - Metastatic Hormone Sensitive Prostate Cancer 15.03.2025 24:30
This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensitive prostate cancer and the use of docetaxel in high and low-volume prostate cancer. Studies discussed in the episode: LATITUDE STAMPEDE For more episodes, resources and blog posts, visit www.inquisiti...
148. Back to Basics - Metastatic Triple Positive (HER2) Breast Cancer 08.03.2025 19:14
As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive cancer's survival is one of the best for metastatic disease, this was not always t...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.